HIV medicine

Sean Emery and David A Cooper
Med J Aust 2002; 176 (1): . || doi: 10.5694/j.1326-5377.2002.tb04254.x
Published online: 7 January 2002

Throughout the world until the mid-1990s, HIV infection was invariably fatal, with a median survival of one to two years after diagnosis of AIDS. Symptomatic HIV disease and AIDS imposed significant burdens on healthcare budgets, in addition to the often immeasurable societal costs. Now, for some, the availability of more effective antiretroviral therapies has transformed the HIV/AIDS epidemic. Mortality and AIDS diagnoses have fallen precipitously since widespread introduction of these treatments.1,2 Evidence to date suggests that the effectiveness of antiretroviral therapy has persisted.3 Mother-to-child HIV transmission can be effectively controlled, so that in the developed world paediatric HIV infection is rare. In developed countries, antiretroviral therapy is one of the most cost-effective interventions for treatment of a chronic disease.4 These unequivocal improvements are largely unprecedented for an infectious disease only 20 years old.

  • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW.



We thank Dr Greg Dore and Dr Tony Kelleher for their critical review of this article.

  • 1. Pallela FJ Jr, Delaney KM, Hoorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 338: 853–860.
  • 2. Correll PK, Law MG, McDonald AM, et al. HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998; 169: 469-472. <eMJA full text>
  • 3. Law MG, Li Y, McDonald A, et al. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS 2000; 14: 197-201.
  • 4. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 334: 817-823.
  • 5. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabtes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.